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Collective evidence indicates that motor neuron degeneration in amyotrophic lateral sclerosis (ALS) is non-
cell-autonomous and requires the interaction with the neighboring astrocytes. Recently, we reported that a
subpopulation of spinal cord astrocytes degenerates in the microenvironment of motor neurons in the
hSOD1G93A mouse model of ALS. Mechanistic studies in vitro identified a role for the excitatory amino
acid glutamate in the gliodegenerative process via the activation of its inositol 1,4,5-triphosphate (IP3)-gen-
erating metabotropic receptor 5 (mGluR5). Since non-physiological formation of IP3 can prompt IP3 receptor
(IP3R)-mediated Ca
21 release from the intracellular stores and trigger various forms of cell death, here we
investigated the intracellular Ca21 signaling that occurs downstream of mGluR5 in hSOD1G93A-expressing
astrocytes. Contrary to wild-type cells, stimulation of mGluR5 causes aberrant and persistent elevations of
intracellular Ca21 concentrations ([Ca21]i) in the absence of spontaneous oscillations. The interaction of
IP3Rs with the anti-apoptotic protein Bcl-XL was previously described to prevent cell death by modulating
intracellular Ca21 signals. In mutant SOD1-expressing astrocytes, we found that the sole BH4 domain of
Bcl-XL, fused to the protein transduction domain of the HIV-1 TAT protein (TAT-BH4), is sufficient to restore
sustained Ca21 oscillations and cell death resistance. Furthermore, chronic treatment of hSOD1G93A mice
with the TAT-BH4 peptide reduces focal degeneration of astrocytes, slightly delays the onset of the disease
and improves both motor performance and animal lifespan. Our results point at TAT-BH4 as a novel gliopro-
tective agent with a therapeutic potential for ALS.
INTRODUCTION
In the adult nervous system, the major glial cell type is repre-
sented by the astrocytes. These cells fulfill several homeostatic
functions that collectively contribute to maintain the optimal
microenvironment for neuronal function and survival (1,2).
In addition, astrocytes can sense neuronal activity by a large
repertoire of neurotransmitter receptors located in their
plasma membrane (3) and, in turn, they can respond to
neurons by Ca2+-dependent release of gliotransmitters (4,5).
The multiplicity and complexity of these activities clearly in-
dicate that the correct performance of the astrocytes is crucial
for the physiological functioning of the nervous system and its
derangement may affect neuronal activity and contribute to
neurodegeneration.
A growing number of recent observations suggests that, in
amyotrophic lateral sclerosis (ALS), a complex pathological
interplay subsists between motor neurons and the neighboring
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glial cells, particularly astrocytes (6–12). Astroglial cells were
described to cause damage to motor neurons directly by releas-
ing toxic factors, but also indirectly via the loss of their
physiological functions (10,11,13–23). Within this frame-
work, we and others reported that a subset of astrocytes, posi-
tioned in the microenvironment of motor neurons, undergoes
degeneration in the spinal cord of transgenic mice over-
expressing the G93A form of mutant human superoxide dis-
mutase 1 (hSOD1G93A) (24,25). This phenomenon occurs
prior to symptom onset and is mediated by the excitatory
amino acid glutamate via the activation of its inositol
1,4,5-triphosphate (IP3)-producing metabotropic receptor
type-5 (mGluR5) (25). The physiological production of IP3
under the stimulation of cell-surface receptors, such as
mGluR5, normally triggers the release of Ca2+ from the endo-
plasmic reticulum (ER) by opening the IP3 receptor (IP3R)
channels. Such Ca2+ plays a role in modulating a variety of
cellular responses that are fundamental for cell function and
survival (26). However, Ca2+ released under non-
physiological conditions can activate different pathways of
cell death (27–31). Importantly, the anti-apoptotic Bcl-2
family members, particularly Bcl-2 and Bcl-XL, were reported
to confer cell death protection by altering the Ca2+ permeabil-
ity of the IP3R channels (29,31–38). The anti-apoptotic activ-
ity of these proteins has been mostly ascribed to their
homology domain 4 (BH4), and the one from Bcl-XL
appears to be more efficient than that of Bcl-2 (39–41).
As a protective role for the Bcl-2 family proteins has been
clearly identified in the mechanisms of cell death triggered
by ALS-linked mutant SOD1s (42–48), here we tested the
impact on astrocyte physiology and survival of a biologically
active peptide consisting of the BH4 domain of Bcl-XL fused
to the protein transduction domain of the human immunodefi-
ciency virus (HIV) TAT protein (TAT-BH4). We report that
although mGluR5-driven degeneration of ALS astrocytes is
coupled to aberrant intracellular Ca2+ handling, the treatment
with TAT-BH4 affords cell death resistance by enhancing pro-
survival Ca2+ oscillations. Furthermore, chronic administra-
tion of TAT-BH4 in vivo, to hSOD1G93A transgenic mice,
reduces degeneration of spinal cord astrocytes, slightly post-
pones the appearance of ALS symptoms and improves both
motor performance and survival.
RESULTS
Aberrant expression of mGluR5 in ALS tissues
A degenerative process of the astrocytes that spatially and
temporally correlates with the progression of ALS disease
was previously identified in the spinal cord of hSOD1G93A
mice (25). Degenerating astroglial cells were morphologically
characterized by an unusually thick and spheroidal cap of glial
fibrillary acidic protein (GFAP) (Fig. 1A, hSOD1G93A, 100
days), which was associated with rare GFAP-positive pro-
cesses and resulted immunopositive for the active caspase-3
(25). Neuropathological analyses of autoptic tissues from
patients affected by sporadic ALS confirmed that these
unusual GFAP- and active caspase-3-positive cellular profiles
are present in the neighborhood of motor neurons also in the
ventral horns of the spinal cord from sALS cases (Fig. 1B
and Supplementary Material, Fig. S1). Because a role for
mGluR5 was originally identified in the gliodegenerative
process in vitro (25), we next investigated the expression of
the receptor messenger RNA (mRNA) in vivo, in the spinal
cord of hSOD1G93A ALS mice and wild-type control
animals, at different ages during disease progression. Quanti-
tative reverse transcription-polymerase chain reaction
(qRT-PCR) analysis revealed that, in wild-type mice,
mGluR5 mRNA levels remain fairly constant throughout life
(Supplementary Material, Fig. S2A). In contrast, at the pre-
symptomatic age of 30 days, the transcripts of the receptor
result up-regulated in hSOD1G93A mice when compared with
age-matched wild-type animals. Yet, their levels significantly
decrease at the time of disease onset, i.e. about 100 days of
age, when the degree of expression becomes comparable
with that in wild-type mice (Supplementary Material,
Fig. S2A).
The expression and cellular distribution of the mGluR5
protein was subsequently explored in situ in mGluR5-
immunolabeled spinal cord sections from hSOD1G93A and
wild-type animals. In both instances, we found that mGluR5
shows the typical punctuate staining of receptor clusters
throughout lumbar spinal cord sections, in both neuronal as
well as glial cells (Fig. 1A and Supplementary Material,
Fig. S2B). However, quantitative analysis of mGluR5-
immunofluorescent puncta confirmed a generally enhanced
expression of the receptor in 30-day-old hSOD1G93A mice
when compared with wild-type animals (Supplementary
Material, Fig. S2C). Because at this phase of the disease, the
degree of expression of the astrocytic and microglial
markers, GFAP and CD11b, was similar in the two genotypes
(GFAP or CD11b expression levels in wild-type mouse spinal
cord were set as 100%; expression levels in 30-day-old
hSOD1G93A mouse spinal cord: GFAP: 75+ 13% versus wild-
type, P ¼ 0.27, unpaired t-test; CD11b: 102+ 15% versus
wild-type, P ¼ 0.12, unpaired t-test, n ¼ 6 fields from three
mice), we infer that the increase in mGluR5 levels is inde-
pendent on hyperproliferation of reactive glia. Rather, it is a
consequence of the presence of mutant SOD1 in the different
cell types. Interestingly, immunohistochemical analyses of
hSOD1G93A spinal cords, taken at the time of disease onset,
confirmed that the expression of mGluR5 was quantitatively
comparable with wild-type spinal cords, but significantly
lower than that in 30-day-old ALS mice (Supplementary Ma-
terial, Fig. S2C). This decrease in the amount of mGluR5
cannot be fully ascribed to motor neuron loss (Fig. 7E), as
we observed a substantial reduction in the expression of the re-
ceptor (227.8+ 2.3%, n ¼ 9 fields from three mice) also in
regions of the spinal cord where the motor cells are still
alive. Noteworthy, at this stage of the disease, degenerating
astrocytes were largely represented and maintained a stronger
immunoreactivity for mGluR5 when compared with the neigh-
boring cells. This profile was determined by enhanced and
closely adjacent mGluR5-positive puncta (Fig. 1A,
hSOD1G93A, 100 days). In keeping with these observations,
we found a similar pattern of mGluR5 expression also in
autoptic sALS spinal cords (Fig. 1B). The fact that mGluR5
is over-expressed in the spinal cord of hSOD1G93A mice at
the pre-symptomatic stage of the disease, but not at the time
of disease onset strongly suggests that this receptor plays a
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crucial role in ALS progression by acting at the early stages of
the disease. Its persistent, enhanced expression in degenerating
astrocytes then indicates that mGluR5 may be involved in the
gliodegenerative process in vivo.
Altered mGluR5-mediated intracellular calcium ([Ca21]i)
signaling in hSOD1G93A-expressing astrocytes is coupled to
cell death
To determine whether the global over-expression of mGluR5
identified in the spinal cord of young ALS mice was reflected
on astrocytes, we next switched to studies in cell culture. First,
we quantified the levels of the receptor mRNA in primary
astrocytes deriving from the spinal cord of newborn
hSOD1G93A and wild-type animals. qRT-PCR analysis indi-
cated that hSOD1G93A-expressing astrocytes show a 2.6-fold
increase in the amount of mGluR5 transcripts when compared
with wild-type sister cultures (Supplementary Material,
Fig. S3). The mGluR5 Ca2+-signaling was then studied by
single-cell Fluo4 imaging of the [Ca2+]i changes induced by
(RS)-3,5-dihydroxyphenylglycine (DHPG), a selective
agonist of the group I metabotropic glutamate receptors
(mGluRs). Consistent with previous reports (49,50), we
found that the majority of wild-type astrocytes (about 68%,
Fig. 2A and C) responded to the local application of 100 mM
DHPG with a single [Ca2+]i transient followed by sustained
[Ca2+]i oscillations (Fig. 2A and C) (49,50). In
hSOD1G93A-expressing astrocytes, the [Ca2+]i signaling fea-
tures were completely different; almost all astrocytes chal-
lenged with DHPG (about 99%) displayed a decreased initial
[Ca2+]i transient (263% of DF/F0 with respect to wild-type
cells, Fig. 2B and C), followed by a secondary long-lasting
rise in cytosolic [Ca2+]i reaching the plateau level in about
10 min. The amplitude of the [Ca2+]i plateau was slightly
heterogeneous, ranging from 0.25 to 0.8 DF/F0, and this
pattern was associated to the lack of oscillatory [Ca2+]i
signals (Fig. 2B and C). Next, we investigated the mechanisms
responsible for this atypical DHPG-induced [Ca2+]i rise in
Figure 1. Distribution of mGluR5 in the spinal cord of hSOD1G93A mice and sporadic ALS patients. (A) Representative images of lumbar spinal cord sections
from 30- (30d) and 100-day-old (100d) wild-type and hSOD1G93A mice. Sections were double-immunostained for GFAP (red) and mGluR5 (green) to visualize
astrocytic cytoskeleton and metabotropic glutamate receptor clusters, respectively. (B) Typical images of human post-mortem ALS spinal cord sections double-
immunolabeled with antibodies against GFAP (red), to mark the astrocytic cytoskeleton, and mGluR5 (green), to visualize the metabotropic glutamate receptor
puncta. (A, B) Dotted lines outline motor neuronal cell bodies. Scale bar, 20 mm.
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ALS astrocytes. We reasoned that the increase in cytosolic
Ca2+ could be caused by stimulated Ca2+ release from
IP3-sensitive intracellular Ca
2+ stores or by increased influx
of extracellular Ca2+.
As it is well known that group I mGluRs are typically
coupled to IP3 formation, and this activates IP3R-mediated
[Ca2+]i signaling, we first explored the involvement of both
the ER Ca2+ stores and the IP3Rs. We found that pre-treatment
with thapsigargin (TG, 1 mM) or cyclopiazonic acid (CPA,
10 mM), two irreversible ER Ca2+-ATPase inhibitors (51,52),
almost completely prevented the DHPG-induced [Ca2+]i
increase in mutant SOD1-expressing cells (Fig. 2D) (53).
Similarly, application of xestospongin C (XeC, 1 mM), a spe-
cific inhibitor of the IP3 receptors (54), reduced the amplitude
of the initial peak to about 20% of the control level and signifi-
cantly decreased the following persistent rise in cytosolic
Ca2+ (285% of DF/F0 with respect to hSOD1
G93A cells,
Fig. 2D and E). The role of extracellular Ca2+ influx was sub-
sequently examined by stimulating hSOD1G93A spinal cord
astrocytes with DHPG in 0 Ca2+ and in the presence of the
Ca2+ chelator ethyleneglycol-bis(b-aminoethyl)-N,N,N′,N′-
tetraacetic acid (EGTA, 5 mM). Consistent with the experi-
ments performed in the presence of Ca2+, DHPG triggered
an initial Ca2+ transient (DF/F0: 0.092+ 0.04) followed by
Figure 2. Impact of hSOD1G93A on DHPG-induced [Ca2+]i signaling in astrocytes. (A–C) Local application of the group I mGluR agonist DHPG induced
[Ca2+]i signaling in wild-type and hSOD1
G93A-cultured astrocytes. (A) Typical single-cell [Ca2+]i transients obtained in response to 100 mM DHPG in three
wild-type astrocytes. Note that the majority of cells (67.7+1.23%; n ¼ 93 cells analyzed; n ¼ 7 experiments) responded with a single [Ca2+]i transient
(DF/F0: 0.27+0.18) followed by sustained [Ca
2+]i oscillations (average frequency: 17+2.5 mHz). (B) As in (A) but in hSOD1
G93A astrocytes. Note that con-
trary to wild-type astrocytes, the majority of hSOD1G93A-expressing cells (99+2.5%; n ¼ 84 cells analyzed; n ¼ 6 experiments) responded to DHPG with a
reduced single [Ca2+]i transient (263%; DF/F0: 0.1+0.08) followed by an abnormal long-lasting calcium rise that reaches the plateau in about 10 min (DF/F0:
0.55+0.3). (C) Summary (mean+ s.e.m.) of .50 cells in multiple trials representing peak amplitude of initial DHPG-evoked [Ca2+]i transient (expressed as
DF/F0) (top) and percentage of cells responding with oscillations (bottom) (
∗P, 0.001, unpaired t-test versus wild-type cells). (D) Summary (mean+ s.e.m.) of
.30 cells in multiple trials representing the [Ca2+]i plateau obtained in hSOD1
G93A astrocytes upon treatment with 100 mM DHPG in the absence or presence of
thapsigargin (1 mM, TG), cyclopiazonic acid (10 mM, CPA), xestospongin C (1 mM, XeC) or 0 Ca2+/EGTA (5 mM). Data are expressed as percentage of DF/F0
calculated in DHPG-treated hSOD1G93A cells (∗P , 0.01, paired t-test versus hSOD1G93A). (E) Typical single-cell [Ca2+]i transients obtained in one
DHPG-treated hSOD1G93A astrocyte in the presence of XeC. Note that the majority of cells treated with XeC (95+3.5%; n ¼ 45 cells analyzed; n ¼ 8 experi-
ments) responded with a reduced single [Ca2+]i transient (DF/F0: 0.050+0.007) followed by a slight, but not significant, increase in calcium (DF/F0: 0.078+
0.01).
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a long-lasting rise in [Ca2+]i reaching a plateau level (DF/F0:
0.23+ 0.16, Fig. 2D) in several minutes. Remarkably, no sig-
nificant differences were found between the conditions with
and without extracellular calcium (Fig. 2D). This suggests
that the DHPG-mediated [Ca2+]i plateau observed in
hSOD1G93A spinal cord astrocytes is not due to the influx of
extracellular Ca2+, but it is mostly caused by the activation
of the IP3 receptors and the release of Ca
2+ from the internal
stores.
Considerable evidence suggests that the function of the ER
is intimately connected with that of mitochondria. Thus,
during normal signaling, there is a continuous flow of Ca2+
between the two organelles, which is relevant for the mito-
chondrial metabolic activity. However, alterations in Ca2+
homeostatic mechanisms that result in massive and/or pro-
longed mitochondrial [Ca2+]i overload can cause the release
of cytochrome c, located between the inner and the outer mito-
chondrial membranes. This event can lead to the activation of
cell death effector caspases (30,31). On the basis of these con-
siderations, we postulated that the unusual efflux of intracellu-
lar Ca2+ detected in the mutant SOD1-expressing cells, in
combination with the loss of IP3R-dependent [Ca
2+]i oscilla-
tions, may underlie degeneration of ALS astrocytes (31). In
agreement with this hypothesis, we confirmed that the same
concentration of DHPG triggers the release of cytochrome c
from mitochondria (Fig. 5A). This event is associated with
delayed (24 h) caspase-3 activation and nuclear condensation
in a subset of mutant SOD1-expressing astrocytes (Fig. 5B).
Because mGluR5, but not the closely related mGluR1 (55),
is expressed in cultured astrocytes, we conclude that the
effects elicited by DHPG in ALS astroglial cells can be
ascribed to mGluR5 activation.
The BH4 domain of Bcl-XL restores [Ca
21]i oscillations in
hSOD1G93A-expressing astrocytes
Several lines of evidence indicate that the Bcl-2 homologs are
important regulators of cell death mechanisms, and this has
been attributed, at least in part, to their ability to modulate
ER Ca2+ signals (29–31,38). Notably, Bcl-XL was reported
to exert its full anti-apoptotic effects by directly binding to
the IP3Rs. This interaction was shown to sensitize cells to
low concentrations of IP3 and enhance spontaneous [Ca
2+]i
oscillations, an event that has been correlated with increased
cell death resistance (36,37). On the basis of this, we next
investigated the expression of Bcl-XL in cultured astrocytes
by immunocytochemistry. Immunofluorescence quantification
revealed that the levels of Bcl-XL were significantly reduced
to 78% in astrocytes harboring mutant SOD1 when com-
pared with wild-type cells (Fig. 3). As the BH4 domain of
Bcl-XL importantly contributes to cell death suppression
(35,39–41), we then examined whether a fusion peptide, in
which BH4 is conjugated with the cell-penetrating TAT
peptide from the HIV-1 virus (TAT-BH4, Supplementary Ma-
terial, Fig. S4A) (56), was transduced into primary astrocytes,
and we studied its stability inside the cells over time. Astro-
glial cells in culture were thus incubated with either unconju-
gated or 5(6)-carboxyfluorescein (FAM)-conjugated
TAT-BH4 (TAT-BH4-FAM, 0.5 mM, 30 min, Supplementary
Material, Fig. S4B). Cells were subsequently washed and
either immediately fixed or maintained in culture for 24 h
and then fixed, according to the timing of our toxicity experi-
ments (25). The presence of TAT-BH4-FAM into nearly 100%
of astrocytes was confirmed by fluorescence microscopy. Fur-
thermore, significant levels of the transduced fluorescent
marker persisted in the astrocytes even 24 h after the
removal of the peptide from the cell culture media (Supple-
mentary Material, Fig. S4B). Noteworthy, analysis of intracel-
lular BH4 levels, using an antibody that reacts with both the
endogenous full-length Bcl-XL protein and the internalized
TAT-BH4 peptide (57), revealed that the treatment with
TAT-BH4 restored 94% of Bcl-XL BH4 levels in mutant
SOD1-expressing astrocytes (Fig. 3).
The efficacy of TAT-BH4 in regulating the [Ca2+]i signal-
ing was then tested in the mutant cells. Calcium imaging
experiments were first carried out by challenging Fluo4-loaded
wild-type and hSOD1G93A-expressing astrocytes with
TAT-BH4 (0.5 mM, 30 min). To our surprise, we found that
the local application of TAT-conjugated BH4 caused an im-
mediate [Ca2+]i rise and restored sustained [Ca
2+]i oscillations
in hSOD1G93A-expressing astrocytes (Fig. 4A). These oscilla-
tions were strongly inhibited in the presence of agents that
either deplete the intracellular Ca2+ stores (TG, 294.5+
3.9% of oscillatory responding cells; n ¼ 50 cells analyzed;
n ¼ 8 experiments) or inhibit the IP3Rs (XeC, 292.5+
Figure 3. Treatment with TAT-BH4 restores normal levels of Bcl-XL BH4 in
hSOD1G93A spinal astrocytes. Astrocyte cultures from the spinal cord of wild-
type or hSOD1G93A mice were treated in the absence or presence of 0.5 mM
TAT-BH4 and immunolabeled for Bcl-XL (red) and TAT (green) proteins.
An antibody that recognizes the amino-terminal BH4 domain of Bcl-XL
(57) and, thus, reacts with both the endogenous full-length protein and the
internalized TAT-BH4 peptide, was used to visualize the global levels of
BH4 within the cells. Inset shows TAT immunoreactivity in hSOD1G93A
cells treated with the peptide. Scale bars, 20 mm. Histograms show the
levels of Bcl-XL BH4 in the different experimental conditions, as determined
by immunofluorescence quantification. Data (mean+ s.e.m.) are expressed as
percentage of Bcl-XL BH4 levels in wild-type astrocytes (n ¼ 50 cells for each
experimental group) (∗∗∗P , 0.0001 versus wild-type astrocytes and 888P,
0.0001 versus hSOD1G93A-expressing astrocytes, one-way ANOVA followed
by Bonferroni post-hoc test).
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4.0% of oscillatory responding cells, n ¼ 53 cells analyzed;
n ¼ 8 experiments; Fig. 4C), thus indicating that TAT-BH4
controls the [Ca2+]i signaling by modulating the IP3R activity.
Administration of the group I mGluR agonist DHPG
(100 mM), 30 min after the application of TAT-BH4, triggered
the typical single [Ca2+]i transient in 99% of the cells, followed
by persistent [Ca2+]i oscillations (Fig. 4A and B). The average
oscillation frequency was similar to that of wild-type cells
(Fig. 4A and D), and these effects were fully dependent on the
release of Ca2+ from the internal stores, as determined by
pharmacological experiments (Fig. 4B and C). On the basis of
these observations, we conclude that the BH4 domain of
Bcl-XL is sufficient to abolish DHPG-dependent unregulated
[Ca2+]i rises and to restore normal spontaneous and evoked
[Ca2+]i oscillations in ALS astrocytes.
TAT-BH4 protects astrocytes from IP3R-driven toxicity by
fine-tuning [Ca21]i signaling
In the next set of experiments, we evaluated whether the res-
toration of physiological [Ca2+]i oscillations in
hSOD1G93A-expressing astrocytes correlated with a gliopro-
tective effect of TAT-BH4 against mGluR5-dependent excito-
toxic damage. Spinal astrocytic cultures from hSOD1G93A or
wild-type mice were pre-incubated in the absence or presence
of 0.5 mM TAT-BH4 for 30 min. The peptide in excess was
then removed and cells were exposed to 100 mM DHPG or
control solution (30 min). In the absence of TAT-BH4, we
confirmed that DHPG induces the release of cytochrome c
from mitochondria (Fig. 5A), an event that is associated to
caspase-3 activation and nuclear condensation selectively in
Figure 4. The TAT-BH4 peptide restores spontaneous and DHPG-evoked [Ca2+]i signaling in hSOD1
G93A-expressing astrocytes. (A) Representative single-cell
[Ca2+]i transients obtained in three hSOD1
G93A-expressing astrocytes treated with TAT-BH4 peptide (0.5 mM; grey traces) for 30 min before the local application
of DHPG (100 mM; black traces). Note that in the presence of TAT-BH4 in 100% hSOD1G93A-expressing astrocytes (n ¼ 90 cells analyzed; n ¼ 8 experiments),
DHPG-evoked [Ca2+]i transients show a pattern similar to that obtained in wild-type astrocytes (Fig. 2A): black traces show a single [Ca
2+]i transient followed
by sustained [Ca2+]i oscillations (average frequency: 14+3.1 mHz). (B) Summary (mean+ s.e.m.) of .40 cells in multiple trials representing the percentage of
cells responding with oscillations per each genotype and treatment (thapsigargin 1 mM, TG; xestospongin C 1 mM, XeC; 0 Ca2+/EGTA 5 mM). Note that TG and
XeC, but not 0 Ca2+/EGTA, strongly inhibited the oscillatory response induced by DHPG in the majority of TAT-BH4-treated hSOD1G93A-expressing astrocytes
(∗P , 0.01 versus TAT-BH4 in wild-type and TAT-BH4 in hSOD1G93A, two-way ANOVA followed by Bonferroni post-hoc test). (C) Typical single-cell
[Ca2+]i transients obtained in response to TAT-BH4 (0.5 mM) and DHPG (100 mM) in one hSOD1
G93A -expressing astrocyte in the presence of XeC. Note
that the treatment with XeC abolished the [Ca2+]i response induced by both TAT-BH4 and DHPG in the majority of cells analyzed (98.5+1.5%; n ¼ 53
cells analyzed; n ¼ 8 experiments). (D) Summary (mean+ s.e.m.) of .50 cells in multiple trials representing the average oscillation frequency induced by
DHPG (100 mM) or TAT-BH4 (0.5 mM) plus DHPG per each genotype and treatment.
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mutant SOD1-expressing astrocytes (Fig. 5B) (25). However,
when astrocytes deriving from hSOD1G93A mice were pre-
treated with the TAT-BH4 peptide, we detected a significant
reduction in both the release of cytochrome c and the apoptotic
parameters (Fig. 5A and B). To ascertain whether the identi-
fied alterations in intracellular Ca2+ signaling strictly
Figure 5. Glioprotective effect of the TAT-BH4 peptide against DHPG toxicity. (A, B) Astrocyte cultures from wild-type or hSOD1G93A mice were pre-treated
in the absence or presence of 0.5 mM TAT-BH4 for 30 min and then incubated with 100 mM DHPG. (A) Representative images of hSOD1G93A-expressing astro-
cytes double-immunolabeled for cytochrome c (Cyt c, green) and the mitochondrial marker manganese superoxide dismutase (SOD2, red); nuclei were stained
with Hoechst 33342 (blue). Scale bar, 20 mm. Note that the treatment with DHPG causes mitochondrial disarrangement and release of Cyt c, as revealed by the
loss of co-localization between Cyt c and SOD2 immunosignals. Pre-treatment with TAT-BH4 restores the complete co-localization of the two proteins, similar
to the situation in control conditions. Histograms show the mean Pearson’s and Manders’ coefficients as calculated using JACoP plug-in of ImageJ software in
the different experimental conditions (see Materials and Methods) (78). Data (mean+ s.e.m.) are expressed as percentage of Pearson’s and Manders’ coefficients
of control condition (control values: Pearson’s coefficient: 0.864+0.008; Manders’ coefficient (M2): 0.728+0.016, n ¼ 25 cells for each experimental con-
dition) (∗P , 0.05 and ∗∗∗P , 0.0001 versus control, 888P , 0.0001 versus DHPG, one-way ANOVA followed by Bonferroni post-hoc test). (B) Treatment with
DHPG induces an increment in the percentage of hSOD1G93A-expressing astrocytes with nuclear condensation and caspase-3 activation as compared with wild-
type cells. Data (mean+ s.e.m.) are expressed as % of control, i.e. the corresponding culture type challenged with saline (control values: cells with condensed
nuclei: wild-type: 0.96+0.07%; hSOD1G93A: 0.98+0.13%; cells immunopositive for active caspase-3: wild-type: 0.32+0.08%; hSOD1G93A: 0.33+0.07%,
n ¼ 3 in triplicate). The presence of TAT-BH4 significantly reduced the percentage of ALS astrocytes showing nuclear condensation and caspase-3 activation
(∗P , 0.05 versus control; ∗∗P , 0.05 versus DHPG, one-way ANOVA followed by Bonferroni post-hoc test). Above the histograms, representative images of
astrocytes with condensed nuclei (Hoechst 33342) and immunopositive for the active caspase-3. Scale bar, 20 mm.
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correlated with the mGluR5-dependent gliodegenerative
process, we subsequently performed single-cell [Ca2+]i
imaging of wild-type astrocytes stimulated with staurosporine
(STS), a well-established pro-apoptotic stimulus that leads to
cell death by causing IP3R-dependent Ca
2+ leak from the
intracellular stores via the activation of IP3Rs (38,58–61).
Similar to DHPG-stimulated ALS astrocytes, we found that
STS (1 mM) triggers a persistent increase in cytosolic
calcium that reaches the plateau in about 75–80 min. This
event is coupled to the absence of evident calcium oscillations
(Fig. 6A). However, when STS was administered 30 min after
the application of TAT-BH4, a significant reduction in the
levels of intracellular calcium (272% with respect to cells
treated with STS alone), coupled to the re-establishment of
[Ca2+]i oscillations, was observed (Fig. 6B). Interestingly,
the variations in [Ca2+]i occurring in the absence or presence
of TAT-BH4 quantitatively correlated with astrocyte degener-
ation. Indeed, in parallel experiments, we found that treating
astrocytes with STS (1 mM) in the absence of the peptide
caused cell death, as determined by nuclear condensation
(Fig. 6C). When cells were pre-incubated with increasing
concentrations of TAT-BH4 (0.1 and 0.5 mM, 30 min),
however, astrocyte degeneration was potently inhibited in a
dose-dependent fashion (Fig. 6C). In view of the impact of
STS on IP3Rs, we conclude that astroglial transduction of
TAT-BH4 is effective in protecting the cells against IP3-
R-driven cell death.
In vivo administration of TAT-BH4 reduces astrocyte
degeneration, slightly postpones disease onset and
improves both motor performance and survival of
hSOD1G93A mice
On the basis of the above observations, we next decided to
assess the therapeutic potential of TAT-BH4 in vivo on ALS
transgenic mice. Starting at the age of 40 days, hSOD1G93A
animals were treated daily with TAT-BH4 (5 mg/kg intraper-
itoneally) or equivalent volumes of vehicle solution (saline).
Thereafter, mice were monitored daily for survival and twice
a week for both decline in body weight and motor perform-
ance, using the rotarod test. As weight gain stops at the time
of disease onset, the peak in the body weight curve was
taken as the earliest measure of the onset of the disease
(8,9). According to this criterion, we found that the disease
manifestation was slightly, but significantly, delayed in mice
injected with TAT-BH4 compared with controls (saline:
99.1+ 2.9 days; TAT-BH4: 107.5+ 1.8 days, n ¼ 14 per ex-
perimental group; P , 0.05, Logrank test; Fig. 7A). In add-
ition, animals treated with the peptide performed
significantly better in the rotarod tasks throughout life
(Fig. 7B) and had a prolonged survival time compared with
vehicle-injected mice (saline: 123+ 2.1 days; TAT-BH4:
138+ 2.1 days, n ¼ 14 per experimental group; P , 0.001,
Logrank test; Fig. 7C). Immunohistochemical analyses were
then performed on spinal cords from a cohort of mice sacri-
ficed at about 100 days of age, i.e. the time of disease onset.
Transduction of the peptide was first evaluated at the cellular
levels by double immunostaining using antibodies for TAT
and the astrocyte- and neuron-specific markers GFAP and
microtubule-associated proteins (MAPs), respectively.
Although robust immunoreactivity was detected in most astro-
cytes, motor neurons showed rather heterogeneous staining,
with some cells displaying a faint immunosignal (Supplemen-
tary Material, Fig. S4C). The expression of mGluR5 was then
analyzed on spinal cord sections from both control and
peptide-treated hSOD1G93A mice double stained for the recep-
tor and GFAP or the neuronal non-phosphorylated neurofila-
ment marker (SMI32). Quantification of mGluR5
immunofluorescence in astrocytes and motor neurons revealed
that the expression and distribution of the receptor was un-
changed upon treatment with TAT-BH4 in both cell types
(mGluR5 expression levels in astrocytes or motor neurons
from control hSOD1G93A mice was set as 100%; mGluR5 ex-
pression levels in TAT-BH4-injected hSOD1G93A mouse
spinal cords: astrocytes: 97.4+ 3.1% versus saline, P ¼
0.50, unpaired t-test; motor neurons: 96.5+ 2.4% versus
saline, P ¼ 0.47, unpaired t-test, n ¼ 6 cells from three
mice). To determine whether the positive effect of the
peptide on disease onset and progression was related to the
identified degenerative process of astrocytes, we next investi-
gated the impact of TAT-BH4 on both glial and neuronal cells.
Figure 6. The TAT-BH4 peptide restores normal [Ca2+]i signaling and sur-
vival in STS-treated wild-type astrocytes in culture. (A) Typical single-cell
[Ca2+]i response of wild-type astrocytes to application of 1 mM STS. Note
that the majority of cells (n ¼ 81 cells analyzed; n ¼ 5 experiments)
responded with an abnormal long-lasting calcium rise that reaches the
plateau in about 75–80 min (DF/F0: 3.52+0.22). (B) Representative single-
cell [Ca2+]i transients obtained in wild-type astrocytes treated with TAT-BH4
peptide (0.5 mM) for 30 min before the local application of STS (1 mM; black
trace). Note that TAT-BH4 reduced the persistent [Ca2+]i rise evoked by STS
(272%; n ¼ 76 cells analyzed; n ¼ 5 experiments) and restored [Ca2+]i oscil-
lations. (C) Astrocyte cultures were pre-incubated for 30 min in the absence
(w/o TAT-BH4) or in the presence of increasing concentrations of
TAT-BH4 (0.1 or 0.5 mM) and then treated with STS (1 mM) for 6 h. The
latter caused an increment in the percentage of cells with nuclear condensa-
tion, whereas the peptide reduced the number of apoptotic cells in a dose-
dependent manner. Data (mean+ s.e.m.) are expressed as % of total cells
(n ¼ 3 in duplicate) (∗P, 0.05 and ∗∗P , 0.01 versus STS w/o TAT-BH4,
one-way ANOVA followed by Bonferroni post-hoc test).
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We found that the treatment with the peptide significantly
reduced the number of spheroid astrocytes immunopositive
for the active caspase-3 located in the motor neuron micro-
environment (274% with respect to saline-treated mice,
Fig. 7D), but not the overall number of GFAP-positive astro-
cytes distributed throughout the spinal ventral horns (saline:
987.7+ 29.1 cells/mm2; TAT-BH4: 917.9+ 33.1 cells/mm2;
n ¼ 18 fields from three mice; P ¼ 0.07, unpaired t-test).
Figure 7. Treatment of hSOD1G93A mice with the TAT-BH4 peptide alleviates the manifestations of the disease. (A) Kaplan–Meier curves represent the ages at
which the disease onset (peak body weight) was reached for saline-treated and TAT-BH4-treated (TAT-BH4, 5 mg/kg i.p. daily) hSOD1G93A mice (n ¼ 14 mice
for each condition). Note that the onset of symptoms in TAT-BH4-treated mice is significantly retarded by 8 days compared with controls (P, 0.05, Logrank
test). (B) Rotarod performance of transgenic hSOD1G93A mice treated with saline or TAT-BH4 (n ¼ 14 mice for each condition). Motor performance is signifi-
cantly improved in hSOD1G93A mice treated with the peptide compared with controls. Data (mean+ s.e.m.) are expressed as the average time of permanence on
the rod of all animals (P , 0.05, repeated-measures ANOVA). (C) Survival analysis of saline- and TAT-BH4-treated hSOD1G93A mice (n ¼ 14 mice for each
condition). The lifespan is significantly extended by 15 days (P, 0.001, Logrank test). The dotted lines in A and C indicate the median values in the two mouse
populations. (D) Representative images of a degenerating astrocyte as defined by GFAP (red) and showing active caspase-3 (blue) and mGluR5 (green) immu-
noreactivity. Scale bar, 10 mm. Histograms indicate the percentage of spheroid astrocytes that are positive for the active caspase-3 in sections from 100-day-old
saline-treated or TAT-BH4-treated hSOD1G93A mice (n ¼ 3 mice for each condition). Data (mean+ s.e.m.) are expressed as % of total active caspase-3-positive
spheroid astrocytes present in 100-day-old saline-treated hSOD1G93A mice (46+16 active-caspase-3-positive astrocytes). The number of caspase-3-positive
cells is significantly lower in the TAT-BH4-treated group (∗P , 0.05 versus saline, unpaired t-test). (E) Histograms show the number of motor neurons in
spinal cord sections from 30-day-old or 100-day-old saline-treated or TAT-BH4-treated hSOD1G93A mice (n ¼ 3 mice for each condition). Data (mean+
s.e.m.) are expressed as % of total motor neurons present in 30-day-old hSOD1G93A mice (596.1+96.14; ∗P, 0.05 versus saline, one-way ANOVA followed
by Bonferroni post-hoc test).
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Noteworthy, the quantity of CD11b-immunopositive micro-
glial cells were slightly, but significantly, decreased upon
chronic injection of TAT-BH4 (saline: 1194+ 20 cells/mm2;
TAT-BH4: 1040.7+ 20.4 cells/mm2; n ¼ 18 fields from
three mice; P , 0.05, unpaired t-test). This result correlated
with the preservation of a greater number of motor neurons
(Fig. 7E). On the basis of these findings, we conclude that
the treatment with TAT-BH4 slightly delays the onset of the
disease, slows the rate of disease progression and reduces de-
generation of astrocytes and motor neurons.
DISCUSSION
Considerable evidence indicates that degeneration of motor
neurons in ALS is non-cell-autonomous and requires com-
bined alterations in motor neurons and the surrounding non-
neuronal cells, particularly astrocytes (6–11,13–23). In this
context, we and others previously described a degenerative
process of the astrocytes located in the neighborhood of
motor neurons in the spinal cord of hSOD1G93A transgenic
mice (24,25). We postulated that astroglial loss may deprive
the adjacent motor neurons of the optimal microenvironment
and, thus, exacerbate their degeneration.
In this study, we further expanded this observation by ana-
lyzing post-mortem tissues from sporadic ALS patients. We
found that gliodegeneration is not only a peculiarity of the
hSOD1G93A mouse model of familial ALS, but occurs also
in the sporadic form of the disease, thus corroborating the rele-
vance of this phenomenon in the context of the human path-
ology. Astrocyte death is not an unusual event in
neurodegenerative disorders characterized by a neuroinflam-
matory response and may represent a self-protective mechan-
ism to limit the intensity and duration of reactive gliosis
(62,63). However, loss of specific subpopulations of astroglia
or those cells located in strategic positions may compromise
neuronal activity and survival by restraining their neuro-
supportive factors and functions (64).
On a mechanistic standpoint, prior studies in vitro implied
the involvement of mGluR5 in the process of astroglial
damage (25). In keeping with this, here we found that dying
astrocytes are strongly immunoreactive for mGluR5 in the
spinal cord of both symptomatic hSOD1G93A mice and autop-
tic sALS cases, suggesting that this receptor may be involved
in the gliodegenerative process also in vivo.
The stage at which mGluR5 becomes relevant for ALS pro-
gression was then investigated by determining the degree of
the receptor expression in the spinal cord of hSOD1G93A
ALS mice. The overall levels of mGluR5 resulted significantly
enhanced in young, pre-symptomatic ALS animals, thus indi-
cating that the receptor is likely to play a major role during the
early phases of the disease. Noteworthy, also neonatal astro-
cytic cultures, prepared from the spinal cord of hSOD1G93A
mice, displayed increased expression of mGluR5 transcripts,
confirming that the up-regulation of mGluR5 occurs during
the early development in ALS astroglia.
In normal astrocytes, the activation of group I mGluRs, in-
cluding mGluR5, triggers the formation of IP3 and the conse-
quent release of Ca2+ from the ER, resulting in intracellular
calcium oscillations (49,50).
In general, Ca2+ released from the intracellular stores is
rapidly taken up by closely juxtaposed mitochondria. An in-
crease in mitochondrial Ca2+ then fine tunes the organelle
function to the enhanced needs of the activated cells (31,65).
However, non-physiological release of Ca2+ from the ER, in
response to IP3 production, may result in mitochondrial
Ca2+ overload and, thus, recruit mitochondria to the apoptotic
cascade (27–31,38). Consistent with this, here we found that
stimulating hSOD1G93A-expressing astrocytes with DHPG, a
group I mGluR agonist, does not produce calcium spiking,
but causes in about 99% of the cells a persistent [Ca2+]i
rise, which is exceptionally elevated in a number of cells.
This event is fully dependent on the Ca2+ efflux from the
ER, suggesting that not only the expression of mGluR5 is
altered in mutant SOD1 astrocytes, but also the function of
its downstream signaling effectors. Misfolded mutant SOD1s
were recently reported not to cause Ca2+ handling defects in
spinal cord mitochondria (24,25,66,67). However, we postu-
lated that an increased release of ER Ca2+ in ALS astrocytes
may enhance mitochondrial Ca2+ uptake and, thus, trigger
astroglial cell death. In keeping with this, here we found
that the abnormal rise in cytosolic calcium triggered by
DHPG correlates with mitochondrial disarrangement, release
of cytochrome c and degeneration of a fraction of ALS astro-
cytes. These results are fully consistent with a previous study
describing reduced capacity of mitochondria from the spinal
cord of mutant SOD1 mice to survive repetitive Ca2+ chal-
lenge (68). Furthermore, they are in agreement with a recent
report describing mitochondrial dysfunction in mutant
SOD1-expressing astrocytes (19).
The IP3R/Ca
2+/apoptosis connection was then further inves-
tigated by stimulating wild-type astrocytes with STS, another
apoptotic stimulus that triggers cell death by disrupting the IP3
receptor-mediated calcium homeostasis (58–61,69). Here we
found that the treatment with STS causes a sustained increase
in [Ca2+]i, which is similar to that triggered by DHPG in ALS
astrocytes, but to higher levels. Also in this case, the [Ca2+]i
rise is associated to degeneration of a significant number of
cells. Interestingly, the [Ca2+]i released by hSOD1
G93A-expres-
sing or wild-type astrocytes treated with DHPG or STS, respect-
ively, quantitatively correlated with the extent of cell
death. Thus, we infer that, in both conditions, it is the persistent
IP3R-mediated Ca
2+ release from the intracellular stores that
underlies astrocyte degeneration. This finding is particularly
interesting in view of previous observations indicating that
IP3R2, the isoform predominantly (or selectively) expressed in
astrocytes (70), is up-regulated in cells from sporadic ALS
patients (71).
Fine tuning of the intracellular Ca2+ homeostasis by the
anti-apoptotic Bcl-2/Bcl-XL proteins was described to
control cell death mechanisms (29,31,38). Although the BH4
domain of Bcl-2 was reported to be necessary and sufficient
to prevent apoptosis by regulating the efflux of calcium from
the ER (35), the role of the N-terminal BH4 domain of
Bcl-XL in modulating pro-survival Ca
2+ signals was not
explored. In this study, we thus investigated the impact of
the BH4 domain of Bcl-XL on astrocyte Ca
2+ signaling by
exploiting a biologically active BH4 peptide fused to the
HIV-1 TAT protein. Consistent with previous evidence using
the full-length Bcl-XL protein (36,37), we found that
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TAT-BH4 modulates the IP3R-dependent Ca
2+ release from
the ER and restores spontaneous Ca2+ oscillations in mutant
SOD1-expressing astrocytes. This tight control of IP3Rs by
the peptide prevents the DHPG-induced aberrant release of
Ca2+ from the intracellular stores and protects the cells from
excitotoxic damage.
The fact that TAT-BH4 re-establishes Ca2+ oscillations and
inhibits astrocyte degeneration in a dose-dependent manner
also upon STS treatment confirms the efficacy of the peptide
towards IP3R-dependent astroglial cell death, thus establishing
a correlation between the deranged mGluR5 Ca2+ signaling
and the degenerative process of hSOD1G93A-expressing astro-
cytes. Further studies are clearly necessary to clarify the
mechanisms by which hSOD1G93A directly or indirectly inter-
feres with mGluR5 signaling in astroglial cells. However, on
the basis of our results, we can hypothesize that the reduction
in Bcl-XL expression identified in ALS astrocytes may
account, at least in part, for the loss of intracellular Ca2+
homeostasis identified in the mutant cells. Furthermore, add-
itional and complementary hypotheses can be formulated
from the available evidence. For example, a recent study indi-
cates that conformational changes of Bcl-2 and exposure of the
pro-apoptotic BH3 domain occur at the mitochondrial mem-
brane in mutant SOD1-expressing cells (72). Considering
that the BH3-containing pro-apoptotic members of the Bcl-2
family proteins were implied in the regulation of ER Ca2+ sig-
naling (73), one can postulate that the occurrence of a similar
event at the ER, due to the accumulation of misfolded mutant
SOD1s within astrocytes (24,25,66,67), might cause derange-
ment of the intracellular Ca2+ homeostasis and trigger Ca2+-
dependent cell death. In both cases, re-introduction of
Bcl-XL BH4, in the form of cell-permeable peptide, over-
comes the biochemical and functional defects triggered by
mutant SOD1 in astrocytes either by reinforcing the endogen-
ous Bcl-XL or by counteracting the deleterious effects of the
BH3 domain.
A crucial indication that astrocyte alterations are implicated
in ALS progression in vivo came from the original observation
that reducing mutant SOD1 expression within astrocytes sig-
nificantly affects the late disease progression in hSOD1G37R
transgenic mice (9). More recent evidence, using the same
genetic approach, then suggested that ablation of the mutant
protein specifically in astrocytes affects disease onset and
early disease progression in hSOD1G85R animals (10).
Although both studies highlight the importance of astroglial
cells in familial ALS, they also suggest that distinct mutations
may differently influence the course of the disease. A role for
hSOD1G93A astrocytes in triggering motor neuron degener-
ation and ALS symptoms in vivo has been clearly demon-
strated in a recent study using a cell transplantation strategy
(11). However, no information is currently available on the
impact of hSOD1G93A astroglial cells on disease progression.
Since intraperitoneal injection of TAT-conjugated proteins
was previously reported to allow an efficient transduction of
the fusion proteins into the brain cells (56), here we investi-
gated the impact on both gliodegeneration and disease pro-
gression of the TAT-BH4 peptide in hSOD1G93A mice, using
this route of administration. The dosage of 5 mg/kg of body
weight was selected in our preclinical trial for two reasons.
First, the acute treatment of mice with equivalent doses of
TAT-Bcl-XL resulted protective against other neurodegenera-
tive conditions, such as ischemic injury of the brain (74).
Second, the chronic administration of similar doses of TAT-
conjugated proteins, on a daily basis, was reported to
produce no signs of neurological impairment or systemic dis-
tress in wild-type mice, thus suggesting no obvious toxicity of
the TAT protein (56). In hSOD1G93A mice, we found that the
prolonged treatment with the peptide, starting at the pre-
symptomatic stage of the disease, slightly delays the onset
of the disease and improves both motor performance and sur-
vival of ALS transgenic mice. These effects are not accompan-
ied by a reduction in the expression of mGluR5 in the different
cell types, possibly because the peptide acts on its downstream
effectors. However, they correlate with a reduction in the
number of astrocytes located in proximity of motor neurons
and expressing the apoptotic effector caspase-3. Noteworthy,
the overall number of astroglial cells that are placed in more
distant positions compared with motor neuronal somas were
unaffected by the treatment. In contrast, microglial cells
were moderately, but significantly, reduced, probably as a con-
sequence of diminished astrocyte degeneration. These results
correlate with the preservation of a greater number of motor
neurons. Whether the effect towards motor neurons is a conse-
quence of the maintenance of a larger number of neuro-
supportive astrocytes in the motor neuron microenvironment
or can be partially ascribed to a direct action of the peptide
on these cells remains to be elucidated. Nevertheless, com-
parative analyses of internalized TAT-BH4 in situ indicate
that the peptide is more easily captured by astrocytes than
motor neurons, suggesting that the major effect may be at
the astroglial level.
In conclusion, our results indicate for the first time the BH4
domain of Bcl-XL as a novel therapeutic for ALS. Further-
more, this study points at cell-permeable peptides as an in-
novative class of drugs suitable for mechanistic studies and
endowed with a potential for curing ALS.
MATERIALS AND METHODS
Transgenic mice and breeding
Transgenic mice expressing human SOD1G93A
(B6SJL-TgN(SOD1-G93A)1Gur) were purchased from the
Jackson Laboratories. The colonies were maintained by breed-
ing hemizygote males to wild-type C57Bl6/SJL F1 hybrid
females. Offspring were genotyped and used for subsequent
studies. Animal procedures were approved by the Italian Min-
istry of Health.
ALS biopsy material
Autoptic tissues from sALS cases were obtained from the
Department of Pathology of the Academic Medical Center
(University of Amsterdam) and the Netherlands ALS Tissue
Bank. Informed consent was obtained for the use of brain
tissue. Tissue was acquired and used in a manner compliant
with the Declaration of Helsinki. All autopsies took place
within 12 h after death.
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All cases were reviewed independently by two neuropathol-
ogists, and the diagnosis of ALS was confirmed according to
the previously described histopathological criteria (75).
Tissue preparation and immunohistological analysis
For mouse tissue preparation, the spine was taken and
immersed in 4% buffered paraformaldehyde for 24 h; spinal
cord was extracted, the lumbar tract was removed and either
paraffin embedded or cryoprotected in 30% sucrose before
freezing. For human tissue preparation, spinal cord was
removed and 0.5-cm thick slices were taken from the cervical
(C7), thoracic (T4 and T8) and lumbar (L1) levels. Slices were
fixed in 10% buffered formalin and embedded in paraffin.
Mouse or human spinal cords were sectioned at 5–10 mm
and used to perform different immunostaining. On selected
sections, the following primary antibodies were used: GFAP
(mouse monoclonal antibody, 1:50, Dako), SMI32 (mouse
monoclonal antibody, 1:500, Covance), MAPs (rabbit poly-
clonal antibody, 1:200, Sigma), CD11b (rat monoclonal anti-
body, 1:500, Serotec), mGluR5 (rabbit polyclonal antibody,
1:100, MBL International Corporation); active caspase-3
(rabbit polyclonal antibody, 1:50, Cell Signalling Technol-
ogy), TAT (mouse monoclonal antibody, 1:10, kindly pro-
vided by Prof. Dag Helland, University of Bergen, Norway).
For active caspase-3 immunostaining, a Tyramide Amplifica-
tion System Kit was used (Perkin Elmer, Inc. ). To resolve
background problems with mouse primary antibody on
murine tissues, a Vectorw M.O.M.TM Immunodetection Kit
(Vector) was used. For histopathological analysis, serial sec-
tions were either immunostained for GFAP/active caspase-3
or treated with 0.5% cresyl violet (Sigma-Aldrich) to detect
motor neuron Nissl substance. GFAP/active caspase-3-
positive astrocytes and motor neurons were counted for a
total of nine disectors using an unbiased stereologic physical
disector technique (76).
Z-axis image stacks (z-step size: 0.5 mm) were collected to
generate three-dimensional data sets of spinal cord sections on
an MRC 1024 Bio-Rad confocal microscope with a 63× Plan
Neofluar NA1,25 oil-immersion objective in condition of
optimal iris diameter as defined by LaserSharp 2000 software.
Quantitative analysis of punctuate mGluR5, GFAP or
CD11b staining was performed on confocal acquired images
(1024 × 1024 pixels) of the spinal cord ventral horns from
both wild-type and hSOD1G93A animals using ImageJ software
(National Institutes of Health, Bethesda, MD, http://rsb.info.
nih.gov/ij/). After establishing an intensity threshold, the soft-
ware calculated the percentage of area occupied by mGluR5,
GFAP or CD11b staining by dividing the area of immunopo-
sitivity by the total area. To quantify the number of GFAP and
CD11b immunopositive cells in the ventral horns of the
lumbar spinal cord, 18 fields/mouse from three animals per
each experimental condition were analyzed by ImageJ soft-
ware (10).
Astrocyte cultures
Primary astrocyte cultures (.99% GFAP-positive) were pre-
pared from the spinal cord of newborn mice (hSOD1G93A or
wild-type littermates) as previously described (25). Once the
cultures reached the confluence, they were re-plated at the
optimal density either in 24-well plates or 35-mm Petri
dishes containing glass coverslips and maintained in
Minimal Essential Medium (MEM, Gibco) supplemented
with 10% fetal bovine serum (Sigma-Aldrich).
Quantitative RT-PCR
Total RNA was extracted from animal tissues or confluent astro-
cytes in culture using RNeasy Mini Kit (Qiagen) according to
the manufacturer’s guidelines. One microgram of tissue- or
astrocyte-extracted total RNA was reverse-transcribed using
iScript cDNA Synthesis Kit according to the manufacturer’s
instructions (Bio-Rad). Two nanograms of the resulting
cDNAs were analyzed by quantitative PCR using the SsoFast
EvaGreen Supermix on a CFX96 Real-Time PCR Detection
System (BIO-RAD). mGluR5-encoding transcripts were
detected using primers 5′-mGluR5-Car (5′-AGCTGTTTT
GTCCACATAT) and 3′-mGluR5-Car (5′-CCAGAGAGTG
TTGAGTTAG). The housekeeping gene hypoxanthine
guanine phosphoribosyl transferase (HPRT) was chosen as a ref-
erence and its mRNA was detected using primers 5′-HPRT
(5′-TGAATCACGTTTGTGTCATTA) and 3′-HPRT (5′-TTC
AACTTGCGCTCATCTTAG).
[Ca21]i imaging
Astrocytes were plated (2.5 × 104 cells/35 mm Petri dish) on
glass coverslips and used 2–3 days later as already shown
(77). Before imaging, cells were loaded with 5 mM
Fluo4-AM (Molecular Probes) for 15–20 min at 378C in a
HEPES-KRH buffer containing (in mM): NaCl 116, KCl 4,
MgCl2 1, CaCl2 1.8, HEPES acid 10, glucose 25 (pH 7.4)
and then allowed to de-esterify for 10 min. After several
washes, coverslips were mounted in an open perfusion micro-
incubator (PDMI-2, Harvard Apparatus) set at 378C on the
stage of the optical recording microscope. During experi-
ments, cells were continuously perfused with HEPES-KRH
(1 ml/min), and stimuli were applied via a software-controlled
micro-perfusion fast-step device (100 ml/min, Warner Instru-
ment Corp.) A Zeiss Axiovert 200 inverted fluorescence
microscope was modified to allow EPI illumination (Visitron
Systems). Fluo4 fluorescence was recorded through a 63×
or 40× objectives lens (Zeiss, Neofluar 63×/1.25 Oil, Neo-
fluar 40×/1.3 Oil) and directed through a Zeiss filter set 10
(BP 450–490; BP 515–565) at 200 or 400 ms intervals by
imaging with excitation light at 488 nm generated by a poly-
chromator illumination system (Visichrome, Visitron
Systems). Video images, digitized with MetaFluor, were ana-
lyzed with MetaMorph software (Universal Imaging). Tem-
poral dynamics of Fluo4 fluorescence have been expressed
as background-subtracted DF/F0 (%), where F0 represents
the fluorescence level of the cells before stimulation and DF
the change in fluorescence occurring during the stimulus.
Pharmacological treatments in vitro
To assess the ability of TAT-BH4 to penetrate into cells, astro-
cytes (8 × 104 cells/well) were plated in 24-well plates con-
taining glass coverslips. Cultures were treated with 10 mg/ml
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Hoechst 33342 (Sigma) for 15 min, quickly washed and incu-
bated with 0.5 mM L-TAT-BH4 (TAT48 – 57 conjugated to the
BH4 domain of Bcl-XL) either unconjugated or conjugated
with 5(6)-carboxyfluorescein (FAM, Primm srl) for 30 min.
Peptides in excess were subsequently removed, cells were
washed and immediately fixed (methanol:acetone, 1:1 for
10 min) or maintained in culture for 24 h and then fixed.
The presence of the peptides inside the cells was evaluated
by a digital camera (DFC 310 FX, Leica Microsystem)
mounted on a DM5000 B microscope (Leica Microsystem)
and analyzed by Leica Application Suite 3.5.0 software.
To test the protective efficacy of TAT-BH4, astrocytes in
culture were pre-exposed to different concentrations of the
peptide (0.1 and/or 0.5 mM, 30 min), washed and then treated
with DHPG (100 mM, 30 min, Tocris Cookson Ltd) or STS
(1 mM, 6 h, Sigma-Aldrich). After removal of DHPG, astro-
cytes were allowed to recover at 378C for 24 h.
Immunocytochemistry and quantitative analysis
Confluent astrocytes were fixed either in 4% buffered parafor-
maldehyde for 15 min at room temperature or in methanol for
10 min at 2208C. Cells were then immunostained using the
following primary antibodies: Bcl-XL (rabbit polyclonal anti-
body, 1:50, Santa Cruz), TAT (mouse monoclonal antibody,
1:10, kindly provided by Prof. Dag Helland, University of
Bergen, Norway), cytochrome c (mouse monoclonal antibody,
1:100, BD Pharmingen), SOD2 (rabbit polyclonal antibody,
1:50, Stressgen), active caspase-3 (rabbit polyclonal antibody,
1:50, Cell Signaling). For quantitative analysis of punctuate
Bcl-XL staining, the total fluorescence of 15 ROI/cell (ROI:
2.09 mm × 2.09 mm) was calculated using ImageJ software
(n ¼ 50 cells per each experimental condition). Cytochrome
c release from mitochondria was determined by its
co-localization with the mitochondrial protein SOD2 using
JACoP plug-in ImageJ. An estimate of the degree of
co-localization was obtained by calculating the Pearson’s
and Manders’ coefficients (78).
The toxic effect of DHPG or STS on cultured astrocytes was
determined by double staining with the fluorescent nuclear dye
Hoechst 33342 and anti-active caspase-3 immunostaining. The
number of astrocytes showing condensed nuclei and activated
caspase-3, 24 h after the pharmacological challenge, was
counted by two independent operators in a blind manner.
The number of dying astrocytes was counted in 8–10 micro-
scopic fields (40×) per coverslip and expressed as percentage
of the total number of cells present in the field.
Pharmacological treatment in vivo
hSOD1G93A mice were administrated daily 5 mg/kg L-
TAT-BH4 peptide (GenScript) or vehicle (PBS containing
10% glycerol) intraperitoneally starting at the age of 40 days
(n ¼ 14 mice for each condition). Mice were thereafter kept
under daily observation and weighted twice a week. Age of
disease onset was retrospectively determined as the time
when mice reached the peak in the body weight. Motor per-
formance was assessed twice a week by rotarod test starting
at the age of 50 days. Briefly, animals were placed on an ac-
celerating rod (Ugo Basile) and the time each mouse remained
on the rod was recorded. The average of three independent
trials per session was used for further analysis of the data.
End stage was defined as the time in which animals were
unable to right themselves within 30 s when placed on their
side.
Statistics. Data are represented as mean+ s.e.m. and statistic-
al significance was verified using GraphPad Prismw software.
Paired or unpaired 2-tailed t-test was used for comparisons
between two groups; one-way or two-way analysis of variance
(ANOVA) followed by Bonferroni post-hoc test was used for
comparisons of multiple groups; repeated-measures two-way
ANOVA was used for behavioral test; the Logrank test was
used for disease onset and survival analysis.
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